HCA Healthcare, Inc. Q4 Profit Increases, Beats Estimates

HCA Healthcare reported Q4 GAAP net income of $1.878 billion ($8.14/share) versus $1.438 billion ($5.63) a year ago, and adjusted EPS of $8.01 which beat the Street estimate of $7.48; revenue rose 6.7% to $19.513 billion. The board authorized up to $10 billion in additional share repurchases and declared a $0.78 quarterly dividend, while fiscal 2026 guidance calls for net income of $6.495B–$7.035B (EPS $29.10–$31.50) and revenue of $76.5B–$80B (consensus EPS $29.45, revenue $79.11B); capex is guided to $5.0B–$5.5B. Shares traded up ~1.7% pre-market.

Analysis

Market structure: HCA's beat (+$8.01 adj EPS vs $7.48 est) and $10B buyback tilt industry economics toward incumbents with scale — HCA, large ambulatory networks and IDNs win via negotiating leverage and outpatient conversion; payers and smaller, leveraged hospitals are pressured as pricing normalization and wage inflation compress margins. The $5–5.5B capex plan signals continued capacity/ambulatory buildout that should sustain revenue growth near guidance (FY26 revenue $76.5–80B).

Risk assessment: Tail risks include adverse CMS/Medicare DRG changes, state Medicaid cuts, a major litigation loss, or a sudden inpatient utilization drop from an epidemiological event; any of these could erase ~10–25% of EPS upside. Near-term (days/weeks) expect a positive sentiment spike; medium-term (3–12 months) buyback execution and FY26 admissions data matter; long-term depends on capex ROI and leverage trends (watch net debt/EBITDA).

Trade implications: Favor HCA (ticker HCA) vs regional peers: establish a 2–4% long position sized to portfolio with staggered entries (add on pullbacks to $460 and $430) and a stop-loss at -12% from entry or on a confirmed guidance cut. Use covered-call overlays (3-month, 5–8% OTM) to harvest yield while buying 9–12 month LEAPS (≈10% OTM) as convex upside exposure; implement a pair trade long HCA / short UHS or CYH to isolate idiosyncratic operational strength.

Contrarian angles: The market may be underpricing regulatory and labor-cost risk — guidance is “in line” not expansive, so limited multiple expansion is likely; buyback could raise leverage if funded by debt, increasing downside in a rising-rate environment. If Q1 admissions miss by >200 bps or CMS issues adverse draft rules in next 60 days, HCA could decline 10–15%, presenting a tactical re-entry opportunity.

Key Decisions for Investors

• Establish a 2–4% portfolio long position in HCA (ticker HCA) over the next 2–6 weeks: scale in at market, add on pullbacks to $460 and $430; set a tactical stop-loss at 12% below your average cost or tighten if guidance is cut.
• Implement a covered-call income sleeve: sell 3-month calls 5–8% OTM on 25–50% of the HCA holding to capture yield while retaining upside; roll or reassess at quarter-ends and after buyback announcements.
• Buy directional convexity: purchase 9–12 month LEAPS (≈10% OTM, e.g., Jan 2027 expiries) sized to ~1% of portfolio to capture upside from buyback/execution while limiting downside to option premium.
• Relative-value pair trade: go long HCA and short a leveraged regional hospital peer (e.g., UHS or CYH) in a 1:1 dollar-neutral size for 3–9 months to play execution and balance-sheet divergence; cut the pair if spread tightens by >150 bps or if HCA guidance is downgraded.
• Monitor catalysts closely: watch CMS rule proposals and state Medicaid budget cycles over the next 30–90 days and HCA Q1 admissions/revenue trends at next earnings — trim or hedge positions if admissions miss guidance by >200 basis points or net debt/EBITDA rises >0.5x year-over-year.